1. Search Result
Search Result
Results for "

mouse fibroblast

" in MedChemExpress (MCE) Product Catalog:

113

Inhibitors & Agonists

3

Fluorescent Dyes

1

Biochemical Assay Reagents

14

Peptides

8

Inhibitory Antibodies

20

Natural
Products

26

Recombinant Proteins

1

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991218
    Anti-IL11 Antibody (X203)
    2 Publications Verification

    EnX203

    Interleukin Related ERK STAT CDK Cadherin Inflammation/Immunology
    Anti-IL11 Antibody (X203) (EnX203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11 . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL11 Antibody (X203)
  • HY-107588
    TC-I 15
    2 Publications Verification

    Integrin Cardiovascular Disease
    TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
    TC-I 15
  • HY-P990117

    Integrin Cardiovascular Disease Cancer
    Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived Osteopontin/SPP1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) blocks Angiotensin II (HY-13948)-induced DNA synthesis and collagen gel contraction in cardiac fibroblasts. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) significantly inhibits tumor growth in CT26 or MC38 tumors mice models .
    Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10)
  • HY-148764

    Cryptochrome Molecular Glues Apoptosis Cancer
    M47 is a molecular glue that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer .
    M47
  • HY-113365

    4-Cholesten-3-one

    Endogenous Metabolite Infection Metabolic Disease
    Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice .
    Cholestenone
  • HY-A0299

    Tripeptide 29

    MMP Inflammation/Immunology
    H-Gly-Pro-Hyp-OH is a collagen-derived peptide and also a dipeptidyl peptidase-4 inhibitor.\nH-Gly-Pro-Hyp-OH inhibits the activity of dipeptidyl peptidase-4 in vitro. H-Gly-Pro-Hyp-OH binds to the DNA-binding site of the JUN/FOS complex, blocks the formation of the DNA-JUN/FOS complex, and inhibits transcriptional activity. H-Gly-Pro-Hyp-OH is applicable to research related to skin photoaging, UVB-induced skin aging/photoaging, and thrombosis .
    H-Gly-Pro-Hyp-OH
  • HY-128895
    KL1333
    1 Publications Verification

    Quinone Reductase Mitochondrial Metabolism Metabolic Disease
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .
    KL1333
  • HY-148098
    Pan KRas-IN-1
    1 Publications Verification

    Ras Cancer
    Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors .
    Pan KRas-IN-1
  • HY-P10728

    RXFP Receptor ERK Cardiovascular Disease Inflammation/Immunology
    B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
    B7-33
  • HY-16160
    Cysmethynil
    1 Publications Verification

    Autophagy ICMT Neurological Disease Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-N0008

    Wnt p38 MAPK mTOR Keap1-Nrf2 TGF-β Receptor Neurological Disease Metabolic Disease
    Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .
    Orcinol glucoside
  • HY-168438
    ERBB agonist-1
    1 Publications Verification

    EGFR Akt ERK Cardiovascular Disease
    ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .
    ERBB agonist-1
  • HY-13488
    HG-10-102-01
    1 Publications Verification

    LRRK2 MNK Neurological Disease
    HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .
    HG-10-102-01
  • HY-173189A

    2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium

    RSV DNA/RNA Synthesis Infection Cancer
    2-5A (2′,5′-ApApA) pentasodium solution 100 mM is a high-affinity (Ka=0.04 nM) RNase L binder. 2-5A pentasodium solution 100 mM activates the nuclease activity of latent RNase L to cleave single-stranded RNA by inducing conformational changes and dimerization of latent RNase L, thereby mediating critical antiviral responses and enhancing interferon effects. 2-5A pentasodium solution 100 mM not only effectively inhibits Rauscher murine leukemia virus replication, reduces viremia and splenomegaly, but also enhances antileukemic efficacy when combined with amphotericin B and exhibits favorable high-dose tolerance. 2-5A pentasodium solution 100 mM is an important tool molecule for investigating the pathological mechanisms of viral infection, hereditary prostate cancer and leukemia .
    2-5A pentasodium solution (100 mM)
  • HY-W002199

    6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol

    Bacterial Apoptosis ERK TNF Receptor Infection Neurological Disease
    6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders .
    6:2 Fluorotelomer alcohol
  • HY-P99047

    AB 0024; GS 6624

    Monoamine Oxidase Cardiovascular Disease Inflammation/Immunology
    Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
    Simtuzumab
  • HY-P1290
    PKA Inhibitor Fragment (6-22) amide
    5 Publications Verification

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with Ki values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC50 of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .
    PKA Inhibitor Fragment (6-22) amide
  • HY-18601
    (±)-BI-D
    Maximum Cited Publications
    6 Publications Verification

    HIV HIV Integrase Infection
    (±)-BI-D is a potent ALLINI (allosteric integrase inhibitor). (±)-BI-D binds integrase at the LEDGF/p75 binding site. (±)-BI-D inhibits HIV-Luc infection in cells (IC50: 0.16 μM in Psip1 knockout E9 mouse embryonic fibroblasts, 2.9 μM in wild-type E9 mouse embryonic fibroblasts) .
    (±)-BI-D
  • HY-137807

    Endogenous Metabolite Cancer
    Thymidine 5′-monophosphate p-nitrophenyl ester sodium (Compound 2a) is the derivative of thymidine 5'-phosphate (TMP). Thymidine 5′-monophosphate p-nitrophenyl ester sodium is potential as an antitumor prodrug .
    Thymidine 5′-monophosphate p-nitrophenyl ester sodium
  • HY-141591

    Biochemical Assay Reagents Others
    CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research .
    CYT296
  • HY-D0967

    Fluorescent Dye Others
    Cy5-bifunctional dye is a bifunctional dye used for covalent labeling of primary amines on proteins or oligonucleotides (Ex/Em = 649 nm/670 nm). Cy5-bifunctional dye can label recombinant annexin-V to assess phosphatidylserine exposure on the cell surface via flow cytometry. Cy5-bifunctional dye can label anti-human IgG (H + L) secondary antibodies. Cy5-bifunctional dye is applicable to studies of glanders and melioidosis .
    Cy5-bifunctional dye
  • HY-160222

    HSV STING IFNAR NF-κB Infection
    HSV-60mer sodium is a 60 bp double-stranded DNA oligonucleotide derived from the HSV-1 genome, and also an IFNβ inducer. HSV-60mer sodium colocalizes with endogenous cytoplasmic IFI16 in immune cells. HSV-60mer sodium activates the transcription factors IRF3 and NF-κB, induces the production of proinflammatory cytokines, and inhibits HSV-1 replication in immune cells. HSV-60mer sodium can be used in studies related to herpes simplex virus type 1 infection .
    HSV-60mer sodium
  • HY-115701

    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-phosphoethanolamine; 15(S)-HpETE-SAPE; 15(S)-hydroperoxyeicostetraenoic acid-SAPE

    Ferroptosis Inflammation/Immunology
    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe is a phospholipid that contains stearic acid (HY-B2219) at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-Pe (SAPE) by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.
    1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe
  • HY-156696

    Na+/H+ Exchanger (NHE) Metabolic Disease
    S3226 is a highly selective NHE-3 inhibitor (IC50<1 μM) that specifically blocks NHE-3-mediated sodium transport. S3226 significantly inhibits blastocyst formation and expansion in mouse embryos, and reduces fluid and electrolyte reabsorption in rat proximal tubules in a dose-dependent manner. S3226 effectively alleviates ischemia-induced acute renal failure by improving renal function parameters, reducing renal tubular injury and restoring intracellular pH homeostasis, without interfering with the normal tubuloglomerular feedback response. S3226 is widely used in studies of acute renal failure and related pathological mechanisms .
    S3226
  • HY-125366

    FAP Metabolic Disease
    ARI-3099 is an oral fibroblast activation protein (FAP) inhibitor. ARI-3099 specifically inhibits the proteolytic activity of FAP and blocks the cleavage of human FGF-21 between residues P171 and S172. ARI-3099 extends the half-life of circulating human FGF-21 in mice. ARI-3099 can be used in the research of type 2 diabetes and metabolic disorders .
    ARI-3099
  • HY-N6701

    Arp2/3 Complex DNA/RNA Synthesis Calcium Channel Inflammation/Immunology
    Dihydrocytochalasin B is an Actin disruptor. Dihydrocytochalasin B disrupts actin microfilament bundles, inhibits actin polymerization, and alters intracellular actin cytoskeletal structures. Dihydrocytochalasin B blocks the initiation of DNA synthesis. Dihydrocytochalasin B inhibits Calcium transport. Dihydrocytochalasin B inhibits cytokinesis and alters cell morphology. Dihydrocytochalasin B can be used in studies related to rickets .
    Dihydrocytochalasin B
  • HY-115930

    Bcl-2 Family Cardiovascular Disease
    Bim-IN-1 is a potent Bim expression inhibitor. Bim-IN-1 reduces Bim expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity .
    Bim-IN-1
  • HY-136093B
    Lixumistat
    1 Publications Verification

    IM156 free base; HL156A free base; HL271 free base

    Mitochondrial Metabolism AMPK Neurological Disease Inflammation/Immunology
    Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
    Lixumistat
  • HY-159768A

    Radionuclide-Drug Conjugates (RDCs) FAP Neurological Disease Cancer
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- 68, lutetium- 177 or terbium- 161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .
    DOTAGA.Glu.(FAPi)2
  • HY-P3513

    ERK MMP Neurological Disease
    β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the Erk1/2, MMP-2 and MMP-9 .
    β-Neo-Endorphin
  • HY-W196368

    COX SARS-CoV Infection Inflammation/Immunology Cancer
    Thymohydroquinone is a COX-2 inhibitor and anti-SARS-CoV-2 agent that induces cytotoxicity, antiproliferative effects and inhibits tumor growth. Thymohydroquinone cannot scavenge superoxide radicals via σ (hydrogen atom transfer) and π-π attacks with superoxide anions. Thymohydroquinone can be used in research related to squamous cell carcinoma, fibrosarcoma and coronavirus disease 2019 (SARS-CoV-2 infection) .
    Thymohydroquinone
  • HY-176798

    Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-P4550

    Endogenous Metabolite Metabolic Disease
    H-Hyp-Gly-OH is a dipeptide containing hydroxyproline and glycine. H-Hyp-Gly-OH promotes the growth of mouse primary fibroblasts on collagen gel. H-Hyp-Gly-OH has potential applications in improving skin by ingesting hydrolyzed collagen. H-Hyp-Gly-OH can be used for metabolic research .
    H-Hyp-Gly-OH
  • HY-164102

    TNF Receptor NF-κB Inflammation/Immunology
    TNF-α-IN-18 (Compound 61) is an inhibitor for TNF-α (IC50 of 1.8 μM), that inhibits TNF signaling pathway through block of NF-kB migration from cytoplasm to nucleus. TNF-α-IN-18 exhibits slight cytotoxicity to mouse fibroblast LM cell, with a CC50 >50 μM. TNF-α-IN-18 ameliorates the TNF- or Lipopolysaccharide (HY-D1056)-induced sepsis in mouse models. TNF-α-IN-18 protects mice from rheumatoid arthritis .
    TNF-α-IN-18
  • HY-P11211

    Antibiotic Bacterial Infection
    D2A21, a cecropin peptide, demonstrates a minimum cidal concentration of 21.69 μg/mL against Chlamydia trachomatis .
    D2A21
  • HY-128034

    PIN1 Cancer
    PPIase-Parvulin inhibitor (compound B) is a cell-permeable inhibitor targeting PPIase Pin1 and Par14, with IC50s of 1.5 and 1.0 µM, respectively. PPIase-Parvulin inhibitor has anticancer activity and inhibits the growth and proliferation of mouse embryonic fibroblasts (MEFs) .
    PPIase-Parvulin inhibitor
  • HY-153413

    Ras Cancer
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .
    Kras4B G12D-IN-1
  • HY-101317
    TAN-67 dihydrobromide
    1 Publications Verification

    SB-205607 dihydrobromide

    Opioid Receptor Neurological Disease
    TAN-67 (SB-205607) dihydrobromide is a potent and selective nonpeptidic δ-opioid receptor agonist with a Ki value of 0.647 nM. TAN-67 dihydrobromide has neuroprotective effect. TAN-67 dihydrobromide can be used in research of ischemic stroke .
    TAN-67 dihydrobromide
  • HY-N7325

    PTEN Orexin Receptor (OX Receptor) Neurological Disease Cancer
    Valerosidate is an OX2R antagonist. Valerosidate increases expression of tumor suppressor proteins p53 and PTEN, selectively reduces colon cancer cell viability, and suppresses colon cancer cell migration. Valerosidate can be used for the research of colon cancer and insomnia .
    Valerosidate
  • HY-124514

    SOS1 Ras ERK Cancer
    UC-857993 is a selective SOS1-Ras inhibitor (Kd=14.7 μM, His6-SOS1cat), suppressing catalytic activity. UC-857993 also inhibits ERK and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .
    UC-857993
  • HY-155732

    Parasite Infection
    NPD-2975 (compound 30) is an orally active antitrypanosomal agent, against Human African Trypanosomiasis (HAT). NPD-2975 has low toxicity potential against human MRC-5 lung fibroblasts, and acute mouse model of T. b. brucei infection. NPD-2975 shows acceptable metabolic stability, inhibits T. b. brucei with IC500 of 70 nM in vitro. NPD-2975 also inhibits CYP enzymes resulted in IC50 values of 0.16 and 0.42 μM against CYP1A2 and CYP2C19, respectively .
    NPD-2975
  • HY-P10720

    Endogenous Metabolite Cardiovascular Disease
    C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger cGMP .
    C-Type Natriuretic Peptide (1-53), Porcine, Rat,mouse
  • HY-122989

    DYRK Inflammation/Immunology
    Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC50= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .
    Aristolactam BIII
  • HY-149708

    ICMT Others
    UCM-13207 is a selective isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor with a human IC50 of 1.4 μM and human Ka of 7.2 μM. UCM-13207 modulates progerin localization, stability, and levels, reduces DNA damage, increases cellular viability, and decreases tissue senescence. UCM-13207 can be used for the research of Hutchinson−Gilford progeria syndrome .
    UCM-13207
  • HY-117000A

    DNA/RNA Synthesis Dihydrofolate reductase (DHFR) Neurological Disease
    D156844 (Compound 11a) hydrochloride is a SMN2 promoter activator with an EC50 of 4 nM. D156844 hydrochloride increases the mRNA expression of the mouse SMN in NSC-34 cells and human SMN2 promoter in severe type I spinal muscular atrophy (SMA) fibroblasts as well as full-length human SMN protein. D156844 hydrochloride overcomes DHFR inhibition. D156844 hydrochloride can be used for SMA research .
    D156844 hydrochloride
  • HY-139062

    C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide

    Apoptosis Ceramidase Autophagy β-catenin Cancer
    C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.
    C6 Urea Ceramide
  • HY-159771

    FAP Cancer
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-115550

    Parasite Infection
    Chalcone 4 hydrate is an anti-parasitic agent. Chalcone 4 hydrate inhibits the growth and proliferation of Babesia and Theileria in vitro. Chalcone 4 hydrate reduces the viability of mammalian fibroblasts and kidney cells in vitro. Chalcone 4 hydrate can be used for the research of parasitic infections .
    Chalcone 4 hydrate
  • HY-N4308

    Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone

    NF-κB IKK Bcl-2 Family Cancer
    Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma .
    Hexamethylquercetagetin
  • HY-P5891

    PKC Cardiovascular Disease
    TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .
    TAT-SAMβA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: